Apoptotic anti-IgE antibodies

Details Apoptotic anti-IgE antibodies Apoptotic anti-IgE antibodies

2008-03-21

2011-12-06

Szperka, Michael (Department: 1644)

Drug, bio-affecting and body treating compositions

Immunoglobulin, antiserum, antibody, or antibody fragment,...

Monoclonal antibody or fragment thereof

C424S133100, C424S139100, C424S141100, C424S143100, C424S178100, C514S001700, C530S387300, C530S387900, C530S388220, C435S331000, C435S343100

Reexamination Certificate

active

08071097

ABSTRACT:
The present application relates to apoptotic anti-IgE antibodies, nucleic acid encoding the same, therapeutic compositions thereof, and their use in the treatment of IgE-mediated disorders.

REFERENCES:
patent: 5079344 (1992-01-01), Chang et al.
patent: 5089603 (1992-02-01), Chang
patent: 5091313 (1992-02-01), Chang
patent: 5231026 (1993-07-01), Chang
patent: 5252467 (1993-10-01), Chang
patent: 5254671 (1993-10-01), Chang
patent: 5260416 (1993-11-01), Chang
patent: 5274075 (1993-12-01), Chang
patent: 5292867 (1994-03-01), Chang
patent: 5310875 (1994-05-01), Chang
patent: 5342924 (1994-08-01), Chang
patent: 5362643 (1994-11-01), Chang
patent: 5420251 (1995-05-01), Chang et al.
patent: 5422258 (1995-06-01), Chang
patent: 5428133 (1995-06-01), Chang
patent: 5449760 (1995-09-01), Chang
patent: 5484907 (1996-01-01), Chang et al.
patent: 5514776 (1996-05-01), Chang
patent: 5543144 (1996-08-01), Chang
patent: 5614611 (1997-03-01), Chang
patent: 5690934 (1997-11-01), Chang et al.
patent: 5866129 (1999-02-01), Chang et al.
patent: 6172213 (2001-01-01), Lowman et al.
patent: WO 89/06138 (1989-07-01), None
patent: WO 90/15614 (1990-12-01), None
patent: WO 91/11456 (1991-08-01), None
patent: WO 92/17207 (1992-10-01), None
patent: WO 99/01556 (1999-01-01), None
patent: WO 2004/070010 (2004-08-01), None
patent: WO 2004/070011 (2004-08-01), None
patent: WO 2007041171 (2007-04-01), None
Chang, T.W., “Developing Antibodies for Targeting Immunoglobulin and Membrane-Bound Immunoglobulin E”Allergy and Asthma Proceedings: The Official Journal of Regional and State Allergy Societies 200627(2):S7-S14 (Mar. 2006).
Chen, H. Y. et al., “Generation and Characterization of Monoclonal Antibodies Against a Segment (epsilonm67) Uniquely Present in Membrane-Bound IgE”FASEB Journal15(5):A1018 (Mar. 8, 2001).
Chen, H. Y. et al., “Monoclonal Antibodies Against the C(epsilon)mX Domain of Human Membrane-Bound IgE and Their Potential Use for Targeting IgE-Expressing B Cells”Int. Arch Allergy Immunology128 (4):315-324 (Aug. 2002).
Feichtner, S. et al., “Targeting the Extracellular Membrane-Proximal Domain of Membrane-Bound IgE by Passive Immunization Blocks IgE Synthesis in Vivo”Journal of Immunology180(8):5499-5505 (Apr. 15, 2008).
Infuhr, D. et al., “Molecular and Cellular Targets of Anti-IgE Antibodies”Allergy60(8):977-985 (Aug. 2005).
Poggianella, M. et al., “The Extracellular Membrane-Proximal Domain of Human Membrane IgE Controls Apoptotic Signaling of the B Cell Receptor in the Mature B Cell Line A20”Journal of Immunology177 (6):3597-3605 (Sep. 15, 2006).
Tumas, D.B. et al., “Anti-IgE Efficacy in Murine Asthma Models is Dependent on the Method of Allergen Sensitization”The Journal of Allergy and Clinical Immunology107 (6):1025-1033 (Jun. 2001).
Anand, S. et al., “Multiple transcripts of the murine immunoglobulin ε membrane locus are generated by alternative splicing and differential usage of two polyadenylation sites”Molecular Immunology34 (2):175-183 (1997).
Batista, F. et al., “The two membrane isoforms of human IgE assemble into functionally distinct B cell antigen receptors”Journal of Experimental Medicine184:2197-2205 (Dec. 1996).
Bozelka, B. et al., “IgE isotype suppression in anti-ε-treated mice”Immunology46:527-532 (1982).
Casale, T. et al., “Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis”J. Allergy Clin. Immunol.100(1):110-121 (Jul. 1997).
Chang, Tse Wen et al., “Anti-IgE antibodies for the treatment of IgE-mediated allergic diseases”Advances In Immunol.93:63-119 (2007).
Chothia and Lesk, “Canonical structures for the hypervariable regions of immunoglobulins”J. Mol. Biol.196:901-917 (1987).
Corne, J. et al., “The effect of intravenous administration of a chimeric anti-IgE antibody on serum IgE levels in atopic subjects: efficacy, safety and pharmacokinetics”J. Clin. Invest.99(5):879-887 (Mar. 1997).
Davis, F. et al., “An epitope on membrane-bound but not secreted IgE: implications in isotype-specific regulation”Bio/Technology9:53-56 (Jan. 1991).
Haak-Frendscho et al., “Administration of an anti-IgE antibody inhibits CD23 expression and IgE production in vivo”Immunology82:306-313 (1994).
Haba and Nisinoff, “Inhibition of IgE synthesis by anti-IgE: Role in long-term inhibition of IgE synthesis by neonatally administered soluble IgE”Proc. Natl. Acad. Sci.USA 87:3363-3367 (May 1990).
Haba and Nisonoff, “Effects of syngeneic anti-IgE antibodies on the development of IgE memory and on the secondary IgE response”J. Immunol.152:51-57 (1994).
Haba and Nisonoff, “Role of antibody and T cells in the long-term inhibition of IgE synthesis”Proc. Natl. Acad. Sci. USA91:604-608 (Jan. 1994).
Hamers-Casterman et al., “Naturally occurring antibodies devoid of light chains”Nature363:446-448 (Jun. 3, 1993).
Heusser, Ch.H. et al., “New concepts of IgE regulation”Int. Arch. Allergy Appl. Immunol.94:87-90 (1991).
Johansson, S.G.O., “IgE in allergic diseases”Proc. roy. Soc. Med.62:37-38 (975-976) (Sep. 1969).
Johnson and Wu, “The Kabat Database and a Bioinformatics Example”Methods in Molecular Biology,Lo ed., Totowa, NJ:Human Press vol. 248:11-25 (2003).
Klubal, R. et al., “The high-affinity receptor for IgE is the predominant IgE-binding structure in lesional skin of atopic dermatitis patients”J. Invest. Dermatol.108:336-342 (1997).
Peng, C. et al., “A new isoform of human membrane-bound IgE”J. Immunol.148:129-136 (Jan. 1, 1992).
Sheriff and Constantine, “Redefining the minimal antigen-binding fragment”Nature Struct. Biol.3(9):733-736 (Sep. 1996).
Stampfli, M. et al., “Inhibition of human IgE synthesis by anti-IgE antibodies requires divalent recognition”Eur. J. of Immunol.24:2161-2167 (1994).
Sun, L. K. et al., “Transfectomas expressing both secreted and membrane-bound forms of chimeric IgE with anti-viral specificity”J. Immunol.146(1):199-205 (Jan. 1, 1991).
Terr, A.I., “The Atopic Diseases”Med. Immunol.,Stites et al., 9th edition, Stamford, Connecticut:Appleton & Lange, Chapter 27, (1997).
Xu and Davis, “Diversity in the CDR3 region of VHis sufficient for most antibody specificities”Immunity13:37-45 (Jul. 2000).
Chen, Jiun-Bo et al., “Unique Epitopes on CεmX in IgE-B Cell Receptors Are Potentially Applicable for Targeting IgE-Committed B Cells”The Journal of Immunology184:1748-1756 (Jan. 2010).
Crestani, E. et al., “In Vivo Association of Cytokine Production and IgE Levels in Infants and Adults”J Allergy Clin Immunol113 (2) :S87 (Feb. 2004).

Affiliated with

Also associated with

Rating

Apoptotic anti-IgE antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Apoptotic anti-IgE antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Apoptotic anti-IgE antibodies will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4268769